Oral MBQ-167 treatment for advanced breast cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1 clinical trial evaluates the safety and effectiveness of MBQ-167, an oral medication, in patients with advanced breast cancer who have not responded to standard treatments. The study involves a dose-escalation approach to determine the maximum tolerated dose and assess side effects. Participants will take the medication twice daily for at least 21 days and undergo regular evaluations and laboratory tests to monitor their health and the drug's impact on cancer progression.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

* The investigator will evaluate these and other criteria to determine whether a participant can be included in this study.
* Histologically and/or cytologically confirmed advanced breast cancer which has progressed after treatment with approved therapies or for which there are no standard therapies available.
* Participants with known brain metastases may be eligible if specific conditions are met.
* Life expectancy ≥6 months, in the opinion of the investigator, after starting MBQ-167.
* Are able to swallow capsules twice daily with a meal.

Key Exclusion Criteria:

* The investigator will evaluate these and other criteria to determine whether a participant should be excluded from this study.
* Inability to take oral medication, or malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea, or vomiting) that might impair the bioavailability of MBQ-167.
* Females who are pregnant or breastfeeding.
* Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.
* Participants who have received any anticancer treatment within 4 weeks or any investigational agent within 28 days prior to the first dose of trial drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.
* Active malignancies other than advanced breast cancer will be excluded from the study.

Where it's running

• Precision Next Gen Oncology & Research Center
  Beverly Hills, California, United States Recruiting
• Florida Cancer Specialists / Sarah Cannon Research Institute / SCRI
  Sarasota, Florida, United States Recruiting
• Sarah Cannon Research Institute/SCRI
  Nashville, Tennessee, United States Recruiting
• FDI Clinical Research
  San Juan, Puerto Rico Completed

Study contacts

• Study coordinator: Scott Houston
• Email: scott.houston@mbqpharma.com
• Phone: (415) 404 8838

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting outcomes for advanced breast cancer patients treated with CDK4/6 inhibitors and endocrine therapy

  This study is trying to see how well different CDK4/6 inhibitors combined with hormone therapy work for people with advanced breast cancer and how safe they are.

  Recruiting at 24 sites Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Aviano and 23 other locations · NCT06805812

• Using tart cherry juice to prevent nerve damage from chemotherapy in breast cancer patients

  This study is testing if drinking tart cherry juice can help prevent nerve damage in breast cancer patients receiving chemotherapy.

  Recruiting Phase 2 University of California, Davis · Sacramento, California · NCT06268665

• ctDNA-guided sequential anti-HER2 therapy with CNS prophylaxis for HER2-positive metastatic breast cancer

  This trial will test whether using regular ctDNA blood tests to guide stepping up or down sequential anti-HER2 treatments, together with local therapies and measures to protect the brain and spinal cord, can produce long-lasting remission for people with HER2-positive stage IV breast cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07459673

• AI-powered mobile app to support chemotherapy for breast cancer

  A mobile app in Arabic uses AI to help women undergoing chemotherapy see if it can improve symptom control and medication adherence compared with standard care.

  Recruiting University of Baghdad · Baghdad · NCT07273812

• Meaning-Centered Therapy for Latinos for adults with advanced cancer

  This study tests whether Meaning-Centered Psychotherapy for Latinos (MCP-L) can reduce anxiety and depression and improve quality of life compared with CBT in Spanish-speaking adults with advanced cancer.

  Recruiting Memorial Sloan Kettering Cancer Center · New York, New York and 1 other locations · NCT07225309

• Radiology-based prediction of HER2 level and T‑DXd benefit in metastatic breast cancer

  This study tests whether patterns in CT or FDG‑PET images can show HER2 level and help predict response to trastuzumab deruxtecan for people with metastatic breast cancer.

  Recruiting Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Milan · NCT07030569

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.